Summary
The endogenous neuropeptide galanin and its associated receptors galanin receptor 1 and galanin receptor 2 are highly localized in brain limbic structures and play an important role in the control of seizures in animal epilepsy models. As such, galanin receptors provide an attractive target for the development of novel anticonvulsant drugs. Our efforts to engineer galanin analogs that can penetrate the blood-brain-barrier and suppress seizures, yielded NAX 5055 (Gal-B2), a systemically-active analog that maintains low nanomolar affinity for galanin receptors and displays a potent anticonvulsant activity. In this report, we show that NAX 5055 is active in three models of epilepsy: 1) the Frings audiogenic seizure-susceptible mouse, 2) the mouse corneal kindling model of partial epilepsy, and 3) the 6 Hz model of pharmacoresistant epilepsy. NAX 5055 was not active in the traditional maximal electroshock and subcutaneous pentylenetetrazol seizure models. Unlike most antiepileptic drugs, NAX 5055 showed high potency in the 6 Hz model of epilepsy across all three different stimulation currents; i.e., 22, 32 and 44 mA, suggesting a potential use in the treatment of pharmacoresistant epilepsy. Furthermore, NAX 5055 was found to be biologically active after intravenous, intraperitoneal, and subcutaneous administration, and efficacy was associated with a linear pharmacokinetic profile. The results of the present investigation suggest that NAX 5055 is a first-in-class neurotherapeutic for the treatment of epilepsy in patients refractory to currently approved antiepileptic drugs.
Article PDF
Similar content being viewed by others
References
Baraban SC, Tallent MK. Interneuron diversity series: interneuronal neuropeptides—endogenous regulators of neuronal excitability. Trends Neurosci 2004;27: 135–142.
Hokfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides—an overview. Neuropharmacology 2000;39: 1337–1356.
Waxham N. Neuropeptides and nitric oxide. In: Byrne JH, ed. Neuroscience Online, 2007. Available at: http://neuroscience.uth.tmc.edu. Accessed July 15, 2007.
Gundlach AL, Jungnickel R-F. Galanin and GALP systems in brain — molecular pharmacology, anatomy, and putative roles in physiology and pathology. In: Kastin AJ, ed. Handbook of biologically active peptides. Amsterdam: Elsevier, 2006: 753–761.
Hawes JJ, Picciotto MR. Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain. J Comp Neurol 2004;479: 410–423.
Goiter JA, van Vliet EA, Aronica E, et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 2006;26: 11083–11110.
Mazarati AM, Halaszi E, Telegdy G. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res 1992;589: 164–166.
Gu XL, Sun YG, Yu LC. Involvement of galanin in nociceptive regulation in the arcuate nucleus of hypothalamus in rats with mononeuropathy. Behav Brain Res 2007; 179: 331–335.
Kanter-Schlifke I, Toft Sørensen A, Ledri M, Kuteeva E, Hökfelt T, Kokaia M. Galanin gene transfer curtails generalized seizures in kindled rats without altering hippocampal synaptic plasticity. Neuroscience 2007;150: 984–992.
Wynick D, Bacon A. Targeted disruption of galanin: new insights from knock-out studies. Neuropeptides 2002;36: 132–144.
Kokaia M, Holmberg K, Nanobashvili A, et al. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci U S A 2001;98: 14006–14011.
Liu HX, Brumovsky P, Schmidt R, et al. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci U S A 2001;98: 9960–9964.
Mahoney SA, Hosking R, Fanant S, et al. The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J Neurosci 2003;23: 416–421.
Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends Pharmacol Sci 2000;21: 109–117.
Lundstrom L, Elmquist A, Bartfai T, Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med 2005;7: 157–180.
Lu X, Lundstrom L, Langel U, Bartfai T. Galanin receptor ligands. Neuropeptides 2005;39: 143–146.
Bulaj G, Green BR, Lee H-K, et al. Design, synthesis and characterization of high-affinity, systemically-active galanin analogs with potent anticonvulsant activities. J Med Chem 2008;51: 8038–8047.
White HS, Watson WP, Hansen SL, et al. First demonstration of a functional role for central nervous system betaine/(gamma)-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J Pharmacol Exp Ther 2005;312: 866–874.
Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47: 217–227.
Matagne A, Klitgaard H. Validation of comeally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res 1998;31: 59–71.
Woodbury LA, Davenport VD. Design and use of a new electro-shock seizure apparatus, and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn Ther 1952;92: 97–104.
Brown WC, Schiffman DO, Swinyard EA, Goodman LS. Comparative assay of antiepileptic drugs by “psychomotor” seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 1953;107: 273–283.
Matagne A, Klitgaard H. Validation of comeally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res Suppl 1998;31: 59–71.
Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32: 281–294.
Dunham MS, Miya TA. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Amer Pharm Ass Sci Ed 1957;46: 208–209.
Finney DJ. Probit Analysis, 3rd ed. London: Cambridge University Press, 1971.
Lang R, Gundlach AL, Kofier B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007;115: 177–207.
Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. Cell Mol Life Sci 2008;65: 1864–1871.
Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors and drug targets. Cell Mol Life Sci 2008;65: 1796–1805.
Heinemann U, Schmitz D, Eder C, Gloveli T. Properties of entorhinal cortex projection cells to the hippocampal formation. Ann N Y Acad Sci 2000;911: 112–126.
Mazarati A, Lundstrom L, Sollenberg U, Shin D, Langel U, Sankar R. Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling. J Pharmacol Exp Ther 2006;318: 700–708.
Bartfai T, Lu X, Badie-Mahdavi H, et al. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A 2004; 101: 10470–10475.
Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A 2002;99: 7136–7141.
Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353: 191–206.
Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993;232: 147–158.
Loscher W. Animal models of epilepsy for the development of anti-epileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002;50: 105–123.
Stables JP, Bertram EH, White HS, et al. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 2002;43: 1410–1420.
Wrenn CC, Holmes A. The role of galanin in modulating stress-related neural pathways. Drug news & perspectives 2006;19: 461–467.
Hygge-Blakeman K, Brumovsky P, Hao JX, et al. Galanin over-expression decreases the development of neuropathic pain-like behaviors in mice after partial sciatic nerve injury. Brain research 2004;1025: 152–158.
Liu H, Hokfelt T. Effect of intrathecal galanin and its putative antagonist M35 on pain behavior in a neuropathic pain model. Brain research 2000;886: 67–72.
Wiesenfeld-Hallin Z, Xu XJ, Langel U, Bedecs K, Hokfelt T, Bartfai T. Galanin-mediated control of pain: enhanced role after nerve injury. Proceedings of the National Academy of Sciences of the United States of America 1992;89: 3334–3337.
Fisone G, Berthold M, Bedecs K, et al. N-terminal galanin-(1–16) fragment is an agonist at the hippocampal galanin receptor. Proceedings of the National Academy of Sciences of the United States of America 1989;86: 9588–9591.
Land T, Langel U, Low M, Berthold M, Unden A, Bartfai T. Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. International journal of peptide and protein research 1991;38: 267–272.
Stohr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy research 2007;74: 147–154.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
White, H.S., Scholl, E.A., Klein, B.D. et al. Developing novel antiepileptic drugs: Characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models. Neurotherapeutics 6, 372–380 (2009). https://doi.org/10.1016/j.nurt.2009.01.001
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2009.01.001